Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTRI/2022/01/039258
CTRI/2022/01/039258Not yet recruitingNot Applicable

Development of Manualized Metacognitive Therapy for Hallucination

Devvarta Kumar1 site in 1 country60 target enrollmentStarted: October 1, 2022Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
60
Locations
1
Primary Endpoint
Changes in the severity of and insight into the hallucinatory experiences of patients with schizophrenia experiencing hallucination
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The study is intended to develop a metacognitive intervention to assist individuals diagnosed with schizophrenia to have better insight into the hallucinatory experiences. The primary focus of therapy will be promoting metacognitive insight into the phenomenology of hallucinations and their cognitive and biological underpinnings. It will be followed by helping patients to relate the learning with their hallucinatory experiences. The whole module will be of 9 sessions of 45-60 minutes

Study Design

Study Type
Interventional
Allocation
Coin toss, Lottery, toss of dice, shuffling cards etc
Masking
Open Label

Eligibility Criteria

Ages
18.00 Year(s) to 50.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • •1.Diagnosis of paranoid or undifferentiated schizophrenia 2.Age between 18-50 years 3.Education, at least, at primary level 4.Conversant in Hindi and/or English.

Exclusion Criteria

  • •â€¢Presence of Formal Thought Disorder •ECT in past 1 month •Alcohol or substance dependence.

Outcomes

Primary Outcomes

Changes in the severity of and insight into the hallucinatory experiences of patients with schizophrenia experiencing hallucination

Time Frame: Base-line, 5 weeks after baseline assessment (post-intervention), 9 weeks after baseline assessment (Follow-up)

Secondary Outcomes

  • Cognitive functions(The assessment will be done at baseline only)
  • Global assessment of functioning(Base-line, 5 weeks after baseline assessment (post-intervention), 9 weeks after baseline assessment (Follow-up))
  • Severity of positive and negative symptoms(Base-line, 5 weeks after baseline assessment (post-intervention), 9 weeks after baseline assessment (Follow-up))
  • Perceived sense of recovery(Base-line, 5 weeks after baseline assessment (post-intervention), 9 weeks after baseline assessment (Follow-up))

Investigators

Sponsor
Devvarta Kumar
Sponsor Class
Other [self]

Study Sites (1)

Loading locations...

Similar Trials

Not yet recruiting
Not Applicable
A psychological Therapy for Hallucinatio
CTRI/2022/01/039258Devvarta Kumar
Completed
Not Applicable
Metacognitive Intervention for Individuals With Severe Mental DisordersSchizophrenia
NCT05556941University of Haifa84
Recruiting
Not Applicable
Metacognitive Training in Ultra-high RiskUltra-high Risk for PsychosisClinical High Risk for PsychosisAt-risk Mental State
NCT05827900Medical University of Vienna30
Enrolling By Invitation
Not Applicable
Metacognitive Therapy for Depression and Generalized Anxiety Disorder in Primary Care, Blended Version of Mediated TreatmentGeneralized Anxiety Disorder
NCT06928428Region Stockholm40
Completed
Not Applicable
Clinical Trial of the Effectiveness of Metacognitive Therapy in the Treatment of Patients With Major Depressive DisorderMajor Depressive Disorder
NCT01608399Norwegian University of Science and Technology40